- Home
- CAL vs TRML Comparison
CAL vs TRML Comparison
Compare CAL & TRML Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CAL
- TRML
- Stock Information
- Founded
- CAL 1878
- TRML 2021
- Country
- CAL United States
- TRML United States
- Employees
- CAL N/A
- TRML N/A
- Industry
- CAL Shoe Manufacturing
- TRML Biotechnology: Pharmaceutical Preparations
- Sector
- CAL Consumer Discretionary
- TRML Health Care
- Exchange
- CAL Nasdaq
- TRML Nasdaq
- Market Cap
- CAL 503.2M
- TRML 598.9M
- IPO Year
- CAL N/A
- TRML N/A
- Fundamental
- Price
- CAL $14.98
- TRML $47.69
- Analyst Decision
- CAL Hold
- TRML Hold
- Analyst Count
- CAL 1
- TRML 12
- Target Price
- CAL $14.00
- TRML $47.04
- AVG Volume (30 Days)
- CAL 934.6K
- TRML 1.8M
- Earning Date
- CAL 09-04-2025
- TRML 11-06-2025
- Dividend Yield
- CAL 1.86%
- TRML N/A
- EPS Growth
- CAL N/A
- TRML N/A
- EPS
- CAL 1.76
- TRML N/A
- Revenue
- CAL $2,652,908,000.00
- TRML N/A
- Revenue This Year
- CAL $1.44
- TRML N/A
- Revenue Next Year
- CAL $5.83
- TRML N/A
- P/E Ratio
- CAL $8.56
- TRML N/A
- Revenue Growth
- CAL N/A
- TRML N/A
- 52 Week Low
- CAL $12.09
- TRML $11.56
- 52 Week High
- CAL $34.53
- TRML $47.77
- Technical
- Relative Strength Index (RSI)
- CAL 49.58
- TRML 94.31
- Support Level
- CAL $14.69
- TRML $22.31
- Resistance Level
- CAL $15.87
- TRML $47.69
- Average True Range (ATR)
- CAL 0.77
- TRML 0.92
- MACD
- CAL -0.05
- TRML 1.57
- Stochastic Oscillator
- CAL 65.37
- TRML 99.71
About CAL Caleres Inc.
Caleres Inc is a footwear company that operates retail shoe stores and e-commerce websites, and designs, develops, sources, manufactures, and distributes footwear for people of all ages. The Company's business operations are organized into two reportable segments - famous Footwear and Brand Portfolio. The famous Footwear segment is comprised of its famous Footwear retail stores, famousfootwear.com, and famousfootwear.ca. The famous Footwear segment operated around 846 stores at the end of 2024. The Brand Portfolio segment offers retailers and consumers a cultivated portfolio of known brands. Geographically, the company generates the majority of its revenue from Domestic operations.
About TRML Tourmaline Bio Inc.
Tourmaline Bio Inc is a late-stage clinical biotechnology company driven by its mission to develop transformative medicines that dramatically improve the lives of patients with life-altering immune diseases. Its initial product candidate is TOUR006, a fully human monoclonal antibody that selectively binds to interleukin-6 (IL-6), a key proinflammatory cytokine involved in the pathogenesis of many autoimmune and inflammatory disorders. The anti-IL-6 and anti-IL-6 receptor (IL-6R) antibody class (IL-6 class) has over two decades of clinical and commercial experience treating over a million patients with a variety of autoimmune and inflammatory diseases.